Boston Scientific Corporation $BSX Shares Sold by Midwest Professional Planners LTD.

Midwest Professional Planners LTD. lessened its position in shares of Boston Scientific Corporation (NYSE:BSX) by 56.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,827 shares of the medical equipment provider’s stock after selling 22,774 shares during the period. Midwest Professional Planners LTD.’s holdings in Boston Scientific were worth $761,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BSX. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the 4th quarter valued at approximately $26,000. Sfam LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. purchased a new position in Boston Scientific during the 4th quarter worth $33,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $48.05 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $69.64 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 1.12 and a beta of 0.57. The stock’s fifty day simple moving average is $46.69 and its 200-day simple moving average is $56.17. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company posted $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BSX. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Raymond James Financial reissued an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Bank of America decreased their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Mizuho decreased their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.